Why I would buy CSL and these ASX healthcare shares

CSL Limited (ASX:CSL) shares are one of three in the healthcare sector that I would buy this month…

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Over the last five years the healthcare sector has vastly outperformed the benchmark ASX 200.

During this time the S&P/ASX 200 Health Care index has provided a gain of 108%, compared to the benchmark index's gain of 20%.

Whilst I don't expect this level of outperformance to continue over the next five years, due to the quality on offer in the sector and favourable tailwinds, I believe it could still generate above-average returns for investors.

With that in mind, here are three healthcare shares I would buy today:

CSL Limited (ASX: CSL)

I think this global biotherapeutics company is arguably the best healthcare share on the Australian market and a great buy and hold option. Thanks to the quality of its portfolio, growing plasma collection network, and significant investment in research and development, I believe CSL is well-positioned to continue delivering above-average earnings growth for the foreseeable future.

Nanosonics Ltd (ASX: NAN)

Another top healthcare share to consider is this infection control specialist. Nanosonics is the company behind the popular trophon EPR product, which is a best in class disinfection system for ultrasound probes. At the last count Nanosonics had an installed base of 19,310 units, up 20% on the prior corresponding period. This compares to an addressable market of 120,000 units. Due to the quality of the product, I expect more market share gains in the coming years, underpinning strong earnings growth. In addition to this, the launch of new products in the coming years could also support its growth and diversify its business.

ResMed Inc (ASX: RMD)

ResMed is a medical device giant focused on creating innovative solutions that treat and keep people out of the hospital. The company aims to do this through a portfolio of cloud-connected devices which care for people with sleep apnoea, chronic obstructive pulmonary disease, and other chronic diseases. Due to the quality of its products and the growing addressable market, I believe ResMed is well-positioned to continue being a market beater over the next decade.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

a happy investor with a wide smile points to a graph that shows an upward trending share price
Growth Shares

Here are the top five ASX 200 shares in Macquarie's model growth portfolio

These ASX 200 shares are highly rated by analysts at Macquarie.

Read more »

a man with a wide, eager smile on his face holds up three fingers.
Growth Shares

3 ASX shares to buy in 2024 and hold for the next 10 years

Analysts think these top shares are in the buy zone right now.

Read more »

A man leans forward over his phone in his hands with a satisfied smirk on his face although he has just learned something pleasing or received some satisfying news.
Growth Shares

4 ASX growth shares I think will benefit from interest rate cuts in 2024

Not only will home loan holders rejoice, investors of these stocks could also be yelling with joy when the Reserve…

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Growth Shares

3 of the best ASX growth shares to buy now

Analysts see plenty of upside for these buy-rated shares.

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Growth Shares

Here's why analysts love these buy-rated ASX 200 growth shares

There's a reason analysts are feeling bullish about these companies.

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Growth Shares

Big returns could be coming for high-flying Lovisa shares

Morgans doesn't believe it is too late to snap up this hot stock.

Read more »

Smiling young parents with their daughter dream of success.
Growth Shares

Why these ASX 200 growth shares could be top buys now

Analysts are feeling bullish about these growth stocks. Let’s see what they’re saying.

Read more »

Concept image of a man in a suit with his chest on fire.
Growth Shares

Ignore the noise and buy this hot ASX growth stock

A recent pullback may have created a buying opportunity according to Bell Potter.

Read more »